Biodesix, Inc. ((BDSX)) has held its Q2 earnings call. Read on for the main highlights of the call.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Biodesix’s latest earnings call struck an optimistic tone as management highlighted robust growth and tightening financial discipline while acknowledging that profitability remains a work in progress. Strong diagnostic momentum, expanding primary care adoption, and best‑in‑class margins were pitched as evidence that the company is steadily de‑risking its path toward break‑even despite lingering losses and cash‑flow sensitivities.

Surging Revenue Underpins Growth Narrative

Biodesix reported Q2 2026 revenue of $26.9 million, a 34% year‑over‑year increase that outpaced many diagnostics peers. Management attributed the top‑line acceleration largely to the performance of its testing franchise, underscoring that growth is coming from core operations rather than one‑off factors.

Diagnostics Remain the Growth Engine

Diagnostic testing revenue reached $25.4 million, up 42% year over year and now represents the clear majority of the business. The company cited both higher test volumes and improved average revenue per test as drivers, suggesting that pricing and mix remain favorable as adoption broadens.

Test Volume Momentum Led by Primary Care

Total test volumes climbed to roughly 20,900 in the quarter, a 38% jump from a year ago as ordering patterns broadened. Primary care volumes were the standout, soaring 133% year over year and now accounting for about 15% of total tests, while pulmonology volumes grew a solid 31%.

Gross Margins Stay Above 80 Percent

Gross margin reached 82% in Q2, improving by 200 basis points from the prior year and marking the fifth straight quarter at or above 80%. Management framed this level as effectively best‑in‑class for diagnostics, providing a strong platform for operating leverage even if further upside is limited.

Operating Leverage Begins to Show

Operating expenses excluding direct costs rose just 7% year over year to $27.4 million, far below the 34% revenue growth rate. The company highlighted this widening gap as evidence that its commercial expansion is scaling efficiently and that fixed costs are being spread over a larger revenue base.

Losses Narrow as Profitability Comes Into View

Net loss for the quarter shrank to $7.3 million, a 37% improvement compared with the prior year as revenue growth outpaced spending. Adjusted EBITDA loss improved even more sharply to $3.2 million, down 56% year over year, signaling tangible progress toward sustained profitability.

Cash Position Strengthens and Burn Rate Falls

Biodesix ended the quarter with $30 million of unrestricted cash, up 17% sequentially, aided by $6.5 million in at‑the‑market equity proceeds. Excluding that financing, net cash used fell to $2.1 million from $6.9 million a year earlier, a roughly 70% improvement that underscores tighter cash management.

Salesforce Expansion Fuels Commercial Scale

The company fielded an average of 104 sales representatives during Q2 and plans to reach about 120 by year‑end 2026. Management aims to add six to eight hires per quarter and believes ongoing gains in sales productivity will sustain volume growth without proportionally higher costs.

Clinical Data Boosts Nodify Adoption

New clinical evidence is playing a key role in driving wider use of the Nodify suite, particularly Nodify CDT. A recent publication showed the test can detect cancer in nodules as small as four millimeters with a low false‑positive rate, while ATS presentations highlighted improved Stage 1 detection and real‑world economic benefits.

Development Services Pipeline Signals External Demand

Biodesix reported approximately $8.5 million in contracted development services work, reflecting ongoing demand from biopharma and other partners. Management emphasized that these external collaborations complement the core diagnostics business, even if the revenue timing can be uneven.

Profitability Still Elusive Despite Progress

Despite the improvements, the company remains in the red, with a $7.3 million net loss and a $3.2 million adjusted EBITDA deficit in Q2. Investors were reminded that further scale and disciplined spending will be needed before Biodesix can consistently generate positive earnings and cash flow.

Lumpy Services Revenue Adds Volatility

Development services revenue slipped to $1.5 million from $2.1 million a year ago, reflecting the timing of project milestones and completions. Management cautioned that this line will remain seasonal and lumpy, creating periodic variability in total revenue even as the underlying demand stays intact.

Operating Spend Still Ahead of the Top Line

Operating expenses excluding direct costs reached $27.4 million, modestly exceeding the $26.9 million in total revenue for the quarter. That gap underscores that Biodesix has more work to do in aligning its cost structure with its revenue base, even as operating leverage improves.

Limited Headroom for Further Margin Expansion

With gross margins already hovering around 80% or higher, management does not foresee major additional gains from cost‑of‑goods improvements. As a result, future profitability improvements will likely depend more on continued revenue growth and disciplined operating expenses than on further margin expansion.

Funding Strategy and Cash Sensitivities

The quarter’s cash balance benefited from the use of an at‑the‑market facility, highlighting ongoing reliance on capital markets. Management argued that current liquidity and contracted services provide sufficient runway, but acknowledged that slower growth or collections could pressure the cash trajectory.

Guidance Reaffirms Confidence in Growth Path

Biodesix reaffirmed full‑year revenue guidance of $108 million to $114 million and signaled confidence in sustaining gross margins near 80% with stable pricing. The company plans to reach about 120 sales reps by the end of 2026, keep operating expenses broadly steady with moderate commercial investments, and drive toward adjusted‑EBITDA profitability as revenue and operating leverage continue to build.

Biodesix’s earnings call painted a picture of a diagnostics company gaining commercial traction and tightening its financial profile while still operating below the profitability line. For investors, the story hinges on whether robust test growth, disciplined expenses, and strong margins can continue long enough to offset residual cash and funding risks and carry the company into sustainable positive earnings.